Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/7517
ANTI-C1Q ANTIBODIES: ASSOCIATION WITH NEPHRITIS AND DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS
Complemento C1q/imunologia
Lúpus Eritematoso Sistêmico/imunologia
Nefrite/imunologia
Adulto
Brasil
Estudos Transversais
Feminino
Técnica Indireta de Fluorescência para Anticorpo
Humanos
Masculino
Meia-Idade
Estatísticas não Paramétricas
Author
Affilliation
Hospital Santo Antônio. Escola Bahiana de Medicina e Saude Publica. Salvador, BA, Brasil.
Hospital do Santa Izabel. Serviço de Reumatologia. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Salvador, BA, Brasil.
INOVA Diagnostics Inc. San Diego, Califórnia, USA.
Escola Bahiana de Medicina e Saúde Publica. Serviço de Reumatologia do Hospital do Santa Izabel. Salvador, BA, Brasil.
Hospital do Santa Izabel. Serviço de Reumatologia. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Salvador, BA, Brasil.
INOVA Diagnostics Inc. San Diego, Califórnia, USA.
Escola Bahiana de Medicina e Saúde Publica. Serviço de Reumatologia do Hospital do Santa Izabel. Salvador, BA, Brasil.
Abstract
BACKGROUND: Anti-C1q antibodies have been described in systemic lupus erythematosus (SLE) as well as in other connective tissue diseases. They have been considered as a marker for disease activity and presence of nephritis. OBJECTIVE: The aim of this study was to determine the prevalence of anti-C1q antibodies in Brazilian lupus patients as well as analyze their association with different clinical and serologic parameters. METHODS: Sera from 81 SLE patients, based on the American College of Rheumatology (ACR) criteria, were collected from a lupus referral outpatient clinic in Salvador, Brazil. Antibodies to C1q were detected by an enzyme-linked immunoassay (ELISA) kit and antibodies to other cellular antigens identified by indirect immunofluorescence on HEp-2 cell substrate (ANA), or Crithidia luciliae (dsDNA), and to nucleosome by ELISA. A cutoff of 20 U was established for anti-C1q and anti nucleosome assays. RESULTS: Anti-C1q antibodies were detected in 39.5% (32/81) of SLE sera. The presence of anti-C1q antibodies was associated with proteinuria (P=0.028) but not with other laboratory or clinical features, such as anti nucleosome or anti-dsDNA antibodies, hematuria, urinary casts or renal failure, leukopenia, pericarditis, pleuritis, malar rash, seizures, and psychosis. There was a positive correlation between the titers of anti-C1q antibodies and the systemic lupuis erythematosus disease activity index (SLEDAI) score (r=0.370; P=0.001). CONCLUSION: This study in Brazilian SLE patients confirms previous findings of the association of anti-C1q antibodies with nephritis and disease activity.
DeCS
Autoanticorpos/análiseComplemento C1q/imunologia
Lúpus Eritematoso Sistêmico/imunologia
Nefrite/imunologia
Adulto
Brasil
Estudos Transversais
Feminino
Técnica Indireta de Fluorescência para Anticorpo
Humanos
Masculino
Meia-Idade
Estatísticas não Paramétricas
Share